Navin Jacob
Stock Analyst at UBS
(2.82)
# 1,727
Out of 4,670 analysts
25
Total ratings
64.29%
Success rate
18.25%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Navin Jacob
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ABBV AbbVie | Maintains: Neutral | $195 → $200 | $176.95 | +13.03% | 11 | Oct 31, 2024 | |
| LLY Eli Lilly | Upgrades: Buy | $363 | $748.01 | -51.47% | 8 | Sep 22, 2022 | |
| RPRX Royalty Pharma | Upgrades: Buy | $51 | $26.43 | +92.96% | 1 | Nov 9, 2020 | |
| GILD Gilead Sciences | Downgrades: Neutral | n/a | $90.19 | - | 1 | Apr 27, 2020 | |
| MRK Merck & Co. | Maintains: Buy | $96 → $92 | $99.18 | -7.24% | 4 | Apr 13, 2020 |
AbbVie
Oct 31, 2024
Maintains: Neutral
Price Target: $195 → $200
Current: $176.95
Upside: +13.03%
Eli Lilly
Sep 22, 2022
Upgrades: Buy
Price Target: $363
Current: $748.01
Upside: -51.47%
Royalty Pharma
Nov 9, 2020
Upgrades: Buy
Price Target: $51
Current: $26.43
Upside: +92.96%
Gilead Sciences
Apr 27, 2020
Downgrades: Neutral
Price Target: n/a
Current: $90.19
Upside: -
Merck & Co.
Apr 13, 2020
Maintains: Buy
Price Target: $96 → $92
Current: $99.18
Upside: -7.24%